| Corbus: Nectin-4 Targeting Proven With U.S. Data On The Way Early 2025 | 06/03 13:03 | seekingalpha.com |
| SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024 | 06/01 10:00 | globenewswire.com |
| Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference | 05/30 08:00 | globenewswire.com |
| Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting | 05/23 17:05 | globenewswire.com |
| Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference | 05/09 08:00 | globenewswire.com |
| Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update | 05/07 08:00 | globenewswire.com |
| Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum | 05/01 08:00 | globenewswire.com |
| Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting | 04/24 16:05 | globenewswire.com |
| These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher? | 04/19 14:30 | investorplace.com |
| Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC | 04/02 08:00 | globenewswire.com |